ARTemis: A randomised trial of bevacizumab with neo-adjuvant chemotherapy (NACT) for patients with HER2-negative early breast cancer: primary endpoint – pathological complete response (pCR)
Authors: Earl, H., Hickish, T. et al.
Conference: NCRI Cancer Conference in the Clinical Trials Showcase
Dates: 2-5 November 2014
Source: Manual
Preferred by: Tamas Hickish